Supercooling in Pharmaceutical Freeze Drying

7/3/202610 min read

Introduction
What Is Supercooling?
Thermodynamic Basis of Supercooling
- Metastable State
- Energy Barrier to Ice Nucleation
- Recalescence
How Supercooling Develops During Pharmaceutical Freeze Drying
Factors Affecting the Degree of Supercooling
- Formulation Composition
- Cooling Rate
- Fill Volume
- Vial Properties
- Dissolved Gases and Particulates
- Freeze Dryer Operating Conditions
Relationship Between Supercooling and Ice Nucleation
Effect of Supercooling on Ice Crystal Formation
Influence on Freeze Concentration
Impact on Primary Drying
Effect on Product Quality
Controlling Supercooling in Pharmaceutical Manufacturing
Practical Considerations During Cycle Development
Frequently Asked Questions
Conclusion
Disclaimer

Introduction

Supercooling is one of the most important freezing phenomena in pharmaceutical lyophilization because it determines when ice nucleation occurs and strongly influences the structure of the frozen product. Although freezing is the first stage of every lyophilization cycle, the extent of supercooling can affect nearly every subsequent process step, including ice crystal size, freeze concentration, mass transfer resistance, primary drying time, and the quality of the final lyophilized cake.

In pharmaceutical manufacturing, formulations rarely freeze exactly at their equilibrium freezing temperature. Instead, they often remain liquid for a short period while cooling below the freezing point. This metastable condition is known as supercooling. Once a stable ice nucleus forms, crystallization proceeds rapidly and establishes the frozen structure that governs drying performance.

Understanding supercooling is essential for robust cycle development and batch consistency. It should also be considered alongside related freezing phenomena such as Ice Nucleation in Lyophilization, Ice Crystal Formation and Growth, Freeze Concentration During Lyophilization, and Freezing Rate in Freeze Drying, all of which collectively determine the quality of the frozen product before Primary Drying begins.

What Is Supercooling?

Supercooling is the process in which a liquid is cooled below its equilibrium freezing temperature without immediately forming ice crystals. Under equilibrium conditions, pure water freezes at approximately 0°C under atmospheric pressure. Pharmaceutical formulations, however, rarely begin freezing at this temperature. Instead, the solution may continue cooling several degrees below its freezing point before the first stable ice crystal forms.

This delay occurs because freezing is not initiated simply by reaching the freezing temperature. The solution must first develop a stable ice nucleus through the process described in Ice Nucleation. Until nucleation occurs, the formulation remains in a liquid but metastable state despite freezing being thermodynamically favorable.

Once nucleation begins, ice crystals grow rapidly throughout the formulation. During this process, the release of latent heat temporarily increases the product temperature, a phenomenon known as recalescence, before cooling resumes. The degree of supercooling is defined as the difference between the equilibrium freezing temperature and the temperature at which ice nucleation actually occurs. For example, if a formulation has an equilibrium freezing point near 0°C but nucleates at –8°C, the degree of supercooling is approximately 8°C.

In pharmaceutical freeze drying, supercooling is not an abnormal event—it is the normal behavior of most aqueous formulations processed in conventional freeze dryers. However, the extent of supercooling varies from vial to vial because nucleation occurs randomly. This variability is one reason why modern pharmaceutical manufacturing increasingly adopts Controlled Nucleation: Principles and Technologies to improve batch uniformity.

Thermodynamic Basis of Supercooling

Supercooling is governed by the relationship between thermodynamics and nucleation kinetics. Although freezing becomes energetically favorable below the equilibrium freezing temperature, the liquid does not immediately transform into ice because an activation energy barrier must first be overcome.

Metastable State

Below the equilibrium freezing point, liquid water enters a metastable state. In this condition, the crystalline phase has lower Gibbs free energy than the liquid phase, meaning ice is the thermodynamically preferred state. However, because no stable crystal nucleus has formed, the liquid continues to exist temporarily. The metastable state is fundamental to pharmaceutical freezing because virtually every lyophilization cycle passes through this region before nucleation occurs.

The thermodynamic principles governing this behavior are discussed more broadly in Thermodynamics, while the influence of pressure and temperature on phase transitions is explained in Water Phase Diagram and Its Importance in Freeze Drying and Triple Point of Water.

Energy Barrier to Ice Nucleation

For ice to form, water molecules must organize into a stable crystalline structure. Creating this initial crystal requires energy because a new solid–liquid interface must be formed. Very small ice embryos are unstable and usually dissolve back into the surrounding liquid. Only when an embryo reaches a critical size does it become energetically stable and continue growing into a larger crystal.

As the solution becomes increasingly supercooled, the thermodynamic driving force for freezing increases and the critical nucleus size decreases. Consequently, deeper supercooling increases the probability that stable nucleation will occur. Because nucleation is a probabilistic event, two identical vials exposed to identical shelf temperatures may nucleate several degrees apart, producing significant variability within a batch.

Recalescence

Once a stable nucleus forms, crystallization proceeds rapidly. Ice formation releases the latent heat of fusion, temporarily raising the product temperature toward the equilibrium freezing temperature. This brief temperature increase is known as recalescence. Recalescence indicates that nucleation has occurred and that rapid ice crystal growth is underway. The size and distribution of these crystals are discussed in detail in Ice Crystal Formation and Growth, where their influence on pore structure and drying performance is examined.

How Supercooling Develops During Pharmaceutical Freeze Drying

Supercooling develops naturally during the freezing stage of a lyophilization cycle. As the shelf temperature decreases, heat is removed from the formulation through the vial, causing the product temperature to fall progressively. When the equilibrium freezing temperature is reached, the formulation does not necessarily freeze immediately. Instead, it often remains liquid while additional cooling continues. During this period, the solution exists in a supercooled metastable state.

Eventually, spontaneous nucleation occurs at one or more locations within the vial. Once a stable nucleus forms, ice crystals grow rapidly throughout the product. The latent heat released during crystallization produces recalescence before the formulation continues cooling to the final freezing temperature. The temperature at which nucleation occurs largely determines the resulting frozen microstructure. Formulations that nucleate at relatively warm temperatures generally produce fewer but larger ice crystals. In contrast, formulations experiencing greater supercooling typically generate many smaller ice crystals, creating a finer pore network after sublimation.

This frozen structure has a direct impact on Freeze Concentration During Lyophilization, Product Resistance (Rp), Heat and Mass Transfer, and ultimately the duration of Primary Drying vs Secondary Drying Explained.

Factors Affecting the Degree of Supercooling

The extent of supercooling varies among formulations and even between individual vials within the same batch. Several formulation, equipment, and process variables influence when nucleation occurs.

Formulation Composition

Dissolved solutes alter the freezing behavior of pharmaceutical formulations by depressing the freezing point and changing solution viscosity. Excipients such as sugars, amino acids, and polymers influence molecular mobility, affecting the probability of nucleation.

The role of formulation components is explored further in Cryoprotectants, Lyoprotectants, Role of Sugars (Sucrose & Trehalose), and Excipients Used in Freeze Drying.

Cooling Rate

Cooling rate strongly influences the degree of supercooling. Rapid cooling generally provides less time for nucleation at higher temperatures, allowing the solution to become more deeply supercooled before freezing begins. Slower cooling often results in earlier nucleation and lower degrees of supercooling. Cooling rate also affects ice crystal morphology and is discussed in detail in Freezing Rate in Freeze Drying.

Fill Volume

Larger fill volumes exhibit different thermal behavior than smaller volumes because heat removal occurs over a greater distance. Changes in thermal gradients within the vial can influence nucleation timing and freezing uniformity. Fill volume also affects heat transfer during drying and contributes to differences in product temperature throughout the cycle.

Vial Properties

Container material, wall thickness, surface characteristics, and geometry all influence heat transfer from the shelf to the product. Minor differences between vials may create slight variations in cooling profiles, contributing to vial-to-vial differences in nucleation temperature. These factors become increasingly important when evaluating Overall Vial Heat Transfer Coefficient (Kv) during process development.

Dissolved Gases and Particulates

Microscopic particles, gas bubbles, or surface imperfections can serve as heterogeneous nucleation sites. Because pharmaceutical formulations are manufactured under highly controlled conditions, they often contain relatively few natural nucleation sites, making supercooling more pronounced. This is one reason why nucleation remains inherently stochastic in conventional freeze dryers.

Freeze Dryer Operating Conditions

Shelf temperature programs, chamber environment, equipment design, and thermal uniformity all influence freezing behavior. Although chamber pressure primarily affects drying rather than freezing, overall equipment performance contributes to temperature uniformity across the batch. Modern systems increasingly incorporate Controlled Nucleation: Principles and Technologies to intentionally reduce variability by initiating nucleation at a predetermined temperature rather than relying on spontaneous freezing.

Relationship Between Supercooling and Ice Nucleation

Supercooling and ice nucleation are inseparable phenomena. Supercooling describes the state in which a solution remains liquid below its equilibrium freezing temperature, while ice nucleation marks the point at which that metastable state ends and crystallization begins. Simply put, supercooling exists because nucleation has not yet occurred.

The extent of supercooling determines the thermodynamic driving force available for nucleation. As the product temperature decreases further below its equilibrium freezing point, the free energy difference between the liquid and solid phases increases. This reduces the critical nucleus size required for stable crystal formation and increases the probability of nucleation.

In conventional pharmaceutical freeze dryers, nucleation occurs randomly (stochastically). Even vials containing the same formulation and processed under identical conditions may nucleate at different temperatures. This vial-to-vial variability is a significant source of process inconsistency because each vial begins crystal growth under slightly different conditions.

Because nucleation determines the starting point of freezing, controlling the nucleation temperature has become an important objective in pharmaceutical manufacturing. Technologies that intentionally initiate nucleation within a narrow temperature range can significantly improve batch uniformity. These technologies are discussed in detail in Controlled Nucleation: Principles and Technologies.

For a comprehensive discussion of nucleation mechanisms, including homogeneous and heterogeneous nucleation, see Ice Nucleation in Lyophilization.

Effect of Supercooling on Ice Crystal Formation

The degree of supercooling has a direct influence on the number, size, and distribution of ice crystals formed during freezing. When nucleation occurs after only slight supercooling, relatively few nuclei are generated. These nuclei have more time and space to grow, producing larger ice crystals. During primary drying, sublimation leaves behind correspondingly larger pores within the dried cake, reducing resistance to water vapor flow.

Conversely, deep supercooling results in the rapid formation of many nuclei. Because numerous crystals compete for the available water, individual crystals remain relatively small. After sublimation, these small crystals create a fine pore network with narrower vapor pathways. The resulting pore structure strongly influences Product Resistance (Rp), one of the most important parameters governing primary drying. Smaller pores increase resistance to vapor flow, slowing sublimation and extending the drying cycle. Larger pores generally reduce resistance, allowing water vapor to escape more efficiently.

Ice crystal morphology also affects the mechanical structure of the final cake, making supercooling an important determinant of product appearance and robustness.

Influence on Freeze Concentration

As ice crystals grow, pure water is removed from the liquid phase and incorporated into the crystalline ice lattice. Solutes—including buffers, sugars, amino acids, proteins, and salts—are excluded from the growing crystals and become concentrated within the remaining unfrozen solution. This process, known as freeze concentration, continues until the formulation reaches its characteristic frozen state.

The degree of supercooling affects how rapidly freezing occurs and therefore influences the spatial distribution of concentrated solutes. Greater supercooling generally produces more rapid crystallization and finer ice crystal networks, while lower supercooling often allows larger crystals to develop and alters the distribution of freeze-concentrated regions.

Freeze concentration has important implications for:

Glass transition temperature (Tg′)
Viscosity of the unfrozen phase
Solute crystallization
Protein stability
Drying behavior

These topics are discussed in greater detail in Freeze Concentration During Lyophilization, Glass Transition Temperature (Tg′ vs Tg), Mannitol Crystallization in Lyophilization, and Cryoprotectants in Lyophilization.

Impact on Primary Drying

The influence of supercooling extends well beyond the freezing stage. Because freezing establishes the pore structure of the dried cake, it directly affects the efficiency of primary drying. Large ice crystals formed after limited supercooling produce larger pores following sublimation. These wider channels allow water vapor to move more easily from the sublimation interface to the drying chamber, reducing mass transfer resistance and shortening primary drying.

In contrast, extensive supercooling creates numerous small ice crystals that leave behind a much finer pore network. These narrow pores restrict vapor transport, increase Product Resistance (Rp), and prolong the primary drying stage.

Supercooling also influences product temperature during drying. Increased resistance to vapor flow can alter heat and mass transfer within the vial, requiring more conservative operating conditions to maintain product temperatures below the Collapse Temperature in Lyophilization or Eutectic Temperature in Freeze Drying, depending on the formulation.

Consequently, freezing conditions established at the beginning of the cycle continue to influence process performance long after freezing has been completed.

Effect on Product Quality

The influence of supercooling extends beyond process efficiency and directly affects critical quality attributes of the finished pharmaceutical product.

Drying Time

Greater supercooling generally produces smaller pores, increasing drying resistance and extending primary drying. Reduced supercooling often results in shorter drying cycles because larger pores facilitate vapor transport.

Cake Structure

The frozen microstructure determines the architecture of the final lyophilized cake. Variations in supercooling can influence pore size, mechanical strength, and overall cake appearance.

Excessive variability may contribute to defects discussed in Common Defects in Lyophilization, including Shrinkage in Lyophilized Products and, in some formulations, Cake Collapse in Lyophilization when process temperatures are not adequately controlled.

Residual Moisture

Changes in pore structure influence drying efficiency and therefore affect residual moisture content at the end of the cycle. Products with higher mass transfer resistance may require longer drying times to achieve the desired moisture specification.

Reconstitution Performance

The internal pore structure created during freezing also influences the rate at which water penetrates the dried cake during reconstitution. A more open pore network generally promotes faster and more uniform wetting.

Batch Uniformity

Perhaps the greatest manufacturing challenge associated with supercooling is batch variability. Since spontaneous nucleation occurs randomly, different vials may develop different frozen structures despite identical process settings. Reducing this variability is one of the primary motivations for implementing controlled nucleation technologies during pharmaceutical freeze drying.

Controlling Supercooling in Pharmaceutical Manufacturing

Although spontaneous supercooling is a natural consequence of freezing, excessive variability is undesirable during commercial manufacturing. Process developers therefore seek to achieve consistent nucleation temperatures across the entire batch.

Several approaches can help reduce variability:

Optimizing shelf cooling profiles
Selecting appropriate formulation compositions
Controlling fill volume and vial configuration
Improving equipment thermal uniformity
Using controlled nucleation technologies

Controlled nucleation intentionally initiates freezing at a predetermined temperature rather than allowing spontaneous nucleation to occur randomly. By narrowing the distribution of nucleation temperatures, manufacturers can produce more uniform ice crystal structures, improve drying consistency, and reduce batch variability.

Practical Considerations During Cycle Development

During lyophilization cycle development, supercooling should be evaluated alongside other critical freezing parameters rather than considered in isolation.

Scientists typically investigate:

Nucleation temperature variability
Ice crystal morphology
Product resistance (Rp)
Primary drying duration
Product temperature profiles
Final cake quality
Residual moisture
Reconstitution characteristics

Laboratory studies often compare different cooling profiles and freezing strategies to determine their effect on drying efficiency and product quality. The ultimate objective is not necessarily to eliminate supercooling but to produce a freezing process that is sufficiently consistent to ensure robust manufacturing performance.

Understanding the relationship between freezing behavior and downstream drying enables more reliable process design, supports scale-up, and contributes to successful commercial manufacturing.

Frequently Asked Questions

Is supercooling desirable in pharmaceutical freeze drying?

Supercooling is a natural part of the freezing process and cannot usually be avoided. The primary objective is to control its variability rather than eliminate it.

Why do identical vials freeze at different temperatures?

Ice nucleation is inherently stochastic in conventional freeze dryers. Small differences in nucleation conditions cause each vial to begin freezing at a slightly different temperature.

Does greater supercooling always produce better products?

No. Greater supercooling typically creates smaller ice crystals and higher drying resistance. The optimal degree of supercooling depends on the formulation, process objectives, and desired product characteristics.

Can supercooling be controlled?

Yes. Modern pharmaceutical freeze dryers may incorporate controlled nucleation technologies that initiate freezing at predetermined temperatures, reducing batch variability.

Conclusion

Supercooling is a fundamental phenomenon that bridges thermodynamics, ice nucleation, crystal growth, and freeze concentration. Although it occurs during the earliest stage of pharmaceutical lyophilization, its effects extend throughout the entire drying cycle by determining pore structure, mass transfer resistance, drying efficiency, and final product quality.

A thorough understanding of supercooling enables scientists and engineers to design more robust freezing processes, improve batch consistency, and optimize lyophilization cycle performance. As pharmaceutical manufacturing increasingly adopts controlled nucleation technologies, managing supercooling has become an essential component of modern freeze-drying process development.

Disclaimer

The information presented in this article is intended exclusively for educational and informational purposes as part of the Lyophilization Core scientific knowledge base. It is designed to support the understanding of pharmaceutical lyophilization science, engineering principles, formulation development, process development, and manufacturing concepts.

This content should not be interpreted as regulatory guidance, GMP instructions, manufacturing procedures, process validation protocols, engineering specifications, or professional consulting advice. The suitability of any lyophilization process, formulation, equipment, or operating condition must be evaluated based on product-specific scientific data, validated procedures, applicable regulatory requirements, and qualified scientific and engineering judgment.

Pharmaceutical development and commercial manufacturing should always be conducted in accordance with applicable Good Manufacturing Practices (GMP), relevant regulatory guidance, approved quality systems, and site-specific standard operating procedures.